TMZ(Temozolomide)

Catalog No.S1237 Batch:S123710

Print

Technical Data

Formula

C6H6N6O2

Molecular Weight 194.15 CAS No. 85622-93-1
Solubility (25°C)* In vitro DMSO 39 mg/mL (200.87 mM)
Water 5 mg/mL (25.75 mM)
Ethanol Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
5%DMSO Corn oil
2.0mg/ml Taking the 1 mL working solution as an example, add 50 μL of 40 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description TMZ(Temozolomide) is a monofunctional SN-1 alkylating agent that can modify nitrogen atoms in the DNA ring and the extracyclic oxygen group, chemically converted to MTIC and degrades to methyldiazonium cation, which transfers methyl groups to DNA at physiologic pH. A DNA damage inducer in L-1210 and L-1210/BCNU cells. Temozolomide induces apoptosis and exhibits antitumor activity.
Targets
DNA replication [1]
(L-1210, L-1210/BCNU cells)
In vitro

Methazolastone causes formation of DNA alkali-labile sites which are present in similar amounts and repaired at a similar rate in L-1210 and L-1210/BCNU cell lines. In L-1210 but not in L-1210/BCNU methazolastone induces an arrest of cells in SL-G2-M phases.[1] Methazolastone sensitivity of both chemo-sensitive and resistant cells (D54-R and U87-R) is enhanced significantly under hyperoxia. Both Methazolastone and hyperoxia are associated with increased phosphorylation of ERK p44/42 MAPK (Erk1/2), but to a lesser extent in D54-R cells, suggesting that Erk1/2 activity may be involved in regulation of hyperoxia and Methazolastone-mediated cell death. Hyperoxia enhances Methazolastone toxicity in GBM cells by induction of apoptosis, possibly via MAPK-related pathways. [2] Methazolastone induces in monocytes the DNA damage response pathways ATM-Chk2 and ATR-Chk1 resulting in p53 activation. [3] Chronic Methazolastone exposure results in acquired Methazolastone-resistance and elevates miR-21 expression. [4] Methazolastone treatment triggers endoplasmic reticula (ER) stress with increased expression of GADD153 and GRP78 proteins, and deceases pro-caspase 12 protein. Methazolastone induces autophagy through mitochondrial damage- and ER stress-dependent mechanisms to protect glioma cells. [5]

In vivo

After a daily i.p. dose of 40 mg/kg for 5 consecutive days (days 1-5 after tumor transplant), methazolastone increases life-span by 86% in L-1210 and 22% in L-1210/BCNU. In L-1210/BCNU no effect is seen after 100 μM or 200 μM treatment; only 400 μM methazolastone produced an accumulation of cells in premitotic phase but much less than in L-1210. In L-1210/BCNU the maximum accumulation of cells in SL-G2-M is, after 48 hours-72 hours, approximately 30% as compared to 23% in untreated cells. Cells accumulates in SL-G2-M occurred too when L- 1210 leukemia-bearing mice are treated i.v. with methazola stone (40 mg/kg). No such effect is seen on L-1210/BCNU cells from mice given the same drug dose. [1]

Features Methazolastone is a second-generation alkylating agent.

Protocol (from reference)

Cell Assay:

[1]

  • Cell lines

    L-1210 and L-1210/BCNU cells

  • Concentrations

    0 μM -100 μM

  • Incubation Time

    l hours

  • Method

    L-1210 and L-1210/BCNU cells are seeded at 0.2 × 104 cells/mL and incubated for 24 hours. The cultures are treated with Methazolastone for l hours at 37oC, then washed twice in PBS by centrifugation and resuspended in fresh medium. Controls and treated samples are diluted in fresh medium 1:4 at 48 hours and 1:2 at 96 hours. Using these dilutions cell concentrations throughout the experiments are between 3 × 105 and 8 × 105/mL. Control growth is logarithmic in this range.

Animal Study:

[1]

  • Animal Models

    DBA/2 mice with L-1210 and L-1210/BCNU cells

  • Dosages

    40 mg/kg

  • Administration

    Administered via i.v.

Customer Product Validation

Data from [Data independently produced by Clin Cancer Res, 2014, 20(6), 1555-65]

Data from [Data independently produced by , , Clin Cancer Res, 2017, 23(20):6239-6253]

Data from [Data independently produced by , , Clin Cancer Res, 2017, 23(2):523-535]

Data from [Data independently produced by , , J Control Release, 2018, 269:245-257]

Selleck's TMZ(Temozolomide) has been cited by 226 publications

Integration of 3D bioprinting and multi-algorithm machine learning identified glioma susceptibilities and microenvironment characteristics [ Cell Discov, 2024, 10(1):39] PubMed: 38594259
GINS2 regulates temozolomide chemosensitivity via the EGR1/ECT2 axis in gliomas [ Cell Death Dis, 2024, 15(3):205] PubMed: 38467631
Patient derived tumoroids of high grade neuroendocrine neoplasms for more personalized therapies [ NPJ Precis Oncol, 2024, 8(1):59] PubMed: 38429350
The combination therapy using tyrosine kinase receptors inhibitors and repurposed drugs to target patient-derived glioblastoma stem cells [ Biomed Pharmacother, 2024, 176:116892] PubMed: 38876048
A Novel Approach for Glioblastoma Treatment by Combining Apoptosis Inducers (TMZ, MTX, and Cytarabine) with E.V.A. (Eltanexor, Venetoclax, and A1210477) Inhibiting XPO1, Bcl-2, and Mcl-1 [ Cells, 2024, 13(7)632] PubMed: 38607071
3D-printed implants loaded with acriflavine for glioblastoma treatment [ Int J Pharm, 2024, 665:124710] PubMed: 39277153
Daurisoline suppress glioma progression by inhibiting autophagy through PI3K/AKT/mTOR pathway and increases TMZ sensitivity [ Biochem Pharmacol, 2024, 223:116113] PubMed: 38460907
Establishment of tumor microenvironment-preserving organoid model from patients with intracranial meningioma [ Cancer Cell Int, 2024, 24(1):36] PubMed: 38238738
Temozolomide and the PARP Inhibitor Niraparib Enhance Expression of Natural Killer Group 2D Ligand ULBP1 and Gamma-Delta T Cell Cytotoxicity in Glioblastoma [ Cancers (Basel), 2024, 16(16)2852] PubMed: 39199623
p53/E2F7 axis promotes temozolomide chemoresistance in glioblastoma multiforme [ BMC Cancer, 2024, 24(1):317] PubMed: 38454344

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.